Exploration of Blood Biomarkers, Including Whole Blood Viscosity as a Prognostic Factor for Acute Pancreatitis

Overview

This study aims to evaluate the usefulness of blood viscosity as a prognostic factor in patients with acute pancreatitis. The study design is a single-arm prospective cohort observational study. Blood biomarkers including blood viscosity, C-reactive protein, hematocrit, and phosphate are measured and the correlation with the severity of acute pancreatitis will be analyzed.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2022

Detailed Description

Several scoring systems are used to evaluate the prognosis of acute pancreatitis, but they are rather complicated and clinically less useful. Blood viscosity is associated with hematocrit and inflammatory factors known to be related to the prognosis of acute pancreatitis, and our group's previous study which is not yet published showed that blood viscosity better predicts severe acute pancreatitis than other single factors such as C-reative protein. Therefore, this study aims to prospectively evaluate the usefulness of blood viscosity as a prognostic factor for acute pancreatitis. During the study period, the study is conducted on patients with acute pancreatitis between the ages of 19 and 70, and patients with acute pancreatitis after ERCP are excluded. Blood viscosities at initial and 24 hours after hospitalization, and serum phosphate, which have shown potential as a predictor of severity in post-ERCP pancreatitis in previous studies are measured. The association of these blood biomarkers with the severity of acute pancreatitis will be analyzed and compared with hematocrit, C-reactive protein, etc., which are known as a single prognostic predictor of acute pancreatitis.

Clinical Trial Outcome Measures

Primary Measures

  • Prediction of severity of acute pancreatitis using initial blood viscosity
    • Time Frame: 48hours after admission
    • Evaluate initial blood viscosity as a predictor of the severity of acute pancreatitis

Secondary Measures

  • Prediction of severity of acute pancreatitis using blood viscosity change after 24hours
    • Time Frame: 24hours after admission
    • Prediction of severity of acute pancreatitis using blood viscosity change after 24hours
  • Prediction of severity of acute pancreatitis using serum phosphate
    • Time Frame: 48hours after admission
    • Prediction of severity of acute pancreatitis using serum phosphate

Participating in This Clinical Trial

Inclusion Criteria

  • Age 19-70 years old – Acute pancreatitis Exclusion Criteria:

  • Post-Endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 70 Years

Investigator Details

  • Lead Sponsor
    • In Seok Lee
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: In Seok Lee, Professor – Seoul St. Mary’s Hospital
  • Overall Official(s)
    • In Seok Lee, MD, PhD, Principal Investigator, Seoul St. Mary’s Hospital
  • Overall Contact(s)
    • Young Hoon Choi, MD, MS, 82-2-2258-6020, crzyzs@naver.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.